Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Tags
Quarterly results

AYTU BIOPHARMA, INC (AYTU) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/06/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
09/27/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
08/15/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/31/2023 8-K Quarterly results
07/10/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
06/12/2023 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Opinion of Dorsey & Whitney LLP",
"Aytu BioPharma Announces Pricing of $4.0 Million Public Offering Priced At-The-Market and the Appointment of a New Director"
05/11/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
05/01/2023 8-K Quarterly results
04/27/2023 8-K Quarterly results
04/19/2023 8-K Quarterly results
03/27/2023 8-K Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S...
02/14/2023 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
01/25/2023 8-K Regulation FD Disclosure, Other Events, Financial Statements and Exhibits  Interactive Data
01/05/2023 8-K Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea...
Docs: "CERTIFICATE OF AMENDMENT OF CERTIFICATE OF INCORPORATION OF AYTU BIOPHARMA, INC.",
"Aytu BioPharma Announces 1-for-20 Reverse Stock Split ENGLEWOOD, CO / January 5, 2023 / Aytu BioPharma, Inc. , a commercial stage pharmaceutical and consumer health company providing pediatric-focused prescription drugs and cost-effective consumer health solutions, today announced a 1-for-20 reverse stock split of its outstanding common stock, effective at 12:01 a.m. Eastern time on January 6, 2023. Beginning tomorrow, January 6, 2023, the Company's common stock will trade on a split-adjusted basis. At the Company's Special Meeting of Stockholders held on October 5, 2022, the Company's stockholders approved a proposal to amend the Company's Certificate of Incorporation to effect a reverse stock split of its common stock at a ratio of up to one-for-twenty , as determined by the Company's Bo..."
12/30/2022 8-K Quarterly results
12/27/2022 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
12/13/2022 8-K Quarterly results
11/30/2022 8-K Quarterly results
11/22/2022 8-K Quarterly results
11/16/2022 8-K Quarterly results
11/15/2022 8-K Quarterly results
11/14/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
11/07/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
10/25/2022 8-K Quarterly results
10/13/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
10/06/2022 8-K Quarterly results
10/05/2022 8-K Quarterly results
09/28/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
09/20/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
09/14/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
08/16/2022 8-K Quarterly results
08/15/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
07/20/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy